Patterns of reverse transcriptase drug resistance

Number of drug resistance mutations (n pts)	Months on ART	Sex	VL at study enrollment (copies/mL)	CD4 at study enrollment (cells/mm³)	NNRTI	NRTI
≥5 (n=8 pts)
1*	48	F	3 010	524	K101E+V108I+Y181C	D67N+K70R+M184V+K219E
2**	49	F	2 680	213	K101H+K103N+V106M+G190A+F227L	D67N+M184V
3*,^	41	F	4 310	354	K101E+V106M+G190A	D67N+M184V
4	44	F	75 000	89	K103N+P225H	D67N+K70R+M184V+T215F+K219E
5*	22	F	1 850	342	K103N+V108I	A62V+V75I+M184V
6*	45	F	773	384	V106M+G190A	M41L+D67N+K70R+M184V
7*	44	F	2 530	199	V106M+Y188LH	D67N+M184V+ K219E
8	45	F	18 200	496	V106M+Y188L	M41L+D67N+K70R+ M184V+T215Y
4 (n=6 pts)
9	15	F	16 900	160	K101E+V108I+G190A	M184V
10	45	F	11 000	464	K101H+K103N+G190A	M184V
11	46	F	3 000	354	K103N+P225H	V75I+M184V
12*	37	M	49 900	16	K103N+Y181C+P225H	M184I
13^	47	F	54 700	419	K103N+G190A+P225H	M184V
14	47	F	9 670	377	K103N+V106A+G190A	K65R
3 (n=10 pts)
15*	48	F	18 300	331	K101E+Y188L	M184I
16	13	F	6 890	214	K101E+V106M	M184V
17	41	F	5 340	319	K103N	D67N+M184V
18*	46	F	407	269	K103N+P225H	M184V
19	47	F	6 510	190	K103N+V108I	M184V
20*	47	F	1 330	277	K103N+V108I	M184V
21	47	M	31 000	99	K103N+V108I	M184V
22**	47	F	1 280	642	K103N+V106M	M184V
23*	40	F	955	276	V106M	A62V+M184V
24	84	F	43 800	174	V106M+Y188C	M184V
2 (n=2 pts)
25	43	M	430	151	K103N	M184V
26**,^	47	F	1 370	320	K103N	M184V
1 (n=5 pts)
27**	44	M	178 000	47	K103N	---
28**	46	F	56 500	187	K103N	---
29**	45	F	42 800	100	K103N	---
30*	45	M	1 130	439	K103N	---
31^	46	F	43 900	193	K103N	---
32	46	F	552	369	No major mutations	No major mutations
33**	41	F	882 000	90	No major mutations	No major mutations
34**	47	F	1 450	192	No major mutations	No major mutations
35*,^	43	M	83 000	103	No major mutations	No major mutations
36^	47	F	77 500	232	No major mutations	No major mutations
37**,^	43	M	312 000	203	No major mutations	No major mutations
38^	50	M	493 000	157	No major mutations	No major mutations
Not amplifiable (n=5 pts)
39	44	F	463	357	---	---
40*,^	43	F	4 660	554	---	---
41**,^	41	M	1 060	430	---	---
42**	13	F	557	445	---	---
43**	55	F	66 800	379	---	---

Pts, patients; F, female; M, male; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI, VL: virus load; *Persistent virologic failure at follow-up; ** Re-suppressed at follow-up; ^ Came late >7 days for the last drug-refill visit

Table 2: Patterns of reverse transcriptase drug resistance mutations

Goto home»